Segmentation by type classifies the market according to the methodological approach employed for biosafety evaluation. In‑vitro assays—including cell‑based cytotoxicity, cytokine release, and genotoxicity tests—constitute the largest share, as they provide high‑throughput, reproducible data for early‑stage candidates. In‑vivo studies, such as rodent repeat‑dose toxicity and immunogenicity assessments, represent a smaller but essential component, required for regulatory submissions where systemic exposure cannot be fully modeled in vitro. Computational modeling and in silico risk assessment tools are emerging, capturing a modest portion of the market while offering cost‑effective scenario analysis for complex biologics. Finally, integrated platforms that combine analytical, bio‑analytical, and safety testing under a single workflow are gaining traction, reflecting a trend toward streamlined CMC operations. This type‑based taxonomy clarifies how each methodological segment contributes to the total market valuation, supporting strategic investment decisions within the broader market taxonomy.